Janssen’s Symtuza has been approved US regulators as the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV in adults.
According to Janssen, single table regimens have the capacity to boost adherence and reduce the medicine burden
Symtuza darunavir (cobicistat/emtricitabine/tenofovir alafenamide) offers patients “the proven protective barrier to resistance of darunavir in a formulation designed for improved tolerability and the convenience,” it said.
Read more: http://www.pharmatimes.com/news/us_approves_janssens_hiv_pill_symtuza_1244683